For infection control and prevention initiatives to be effective in preventing the spread of methicillin-resistant Staphylococcus aureus (MRSA) within healthcare facilities, prompt identification of this pathogen from clinical samples is fundamental. MRSASelect (Bio-Rad, Marnes-la-Coquette, France) is a new chromogenic agar that permits presumptive identification of MRSA directly from clinical specimens such as nasal swabs. Robust colonies with strong pink coloration appearing on MRSASelect agar within 24 hours of incubation are considered MRSA and do not require supplemental testing before reporting the result. The selectivity of MRSASelect is based upon the combined suppressive effects of a high NaCl concentration and a proprietary mixture of antibacterial and antifungal agents that inhibit the majority of normal flora and potentially pathogenic microorganisms other than MRSA.
Here we report a clinical isolate of Staphylococcus cohnii which produced strongly pink colonies on MRSASelect within 24 hours of growth. The isolate was obtained from a swab of the anterior nares submitted to the clinical microbiology laboratory for MRSA screening of a patient who was known to be previously colonized with MRSA. The swab was inoculated directly onto MRSASelect and also into an enrichment broth (Brain Heart Infusion broth supplemented with ceftizoxime, 5 µg/ml, and aztreonam, 75 µg/ml) (6), incubated overnight at 35°C, and then 100 µl plated to MRSASelect. The directly plated MRSASelect revealed no pink colonies at 24 hours. The MRSASelect inoculated with the aliquot of enrichment broth grew many strongly pink colonies (0.8 mm diameter) at 24 hours ( Figure 1 ). This result was reported as positive for MRSA. Prior to collection of this specimen, the patient had undergone decolonization using topical and systemic antibiotics (mupirocin, 2% cream, applied three times daily; trimethoprim-sulfamethoxazole, 160 mg/800 mg orally, twice daily; and doxycycline, 100 mg orally, twice daily) for 14 days, with 5 subsequent weekly negative MRSA screening
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on July 10, 2017 by guest http://jcm.asm.org/ Downloaded from cultures. Because of the "re-colonization" of the patient with MRSA, the infection control service requested pulsed-field gel electropheresis (PFGE) of the isolate to determine its relationship to the patient's previous isolate. As well, screening specimens from all patients on the same ward as the MRSA-positive patient were submitted to the clinical microbiology laboratory. In preparation for PFGE, the initial isolate was sub-cultured onto a blood agar plate.
After 24 hours of incubation, off-white, non-hemolytic colonies appeared that were slide coagulase-and tube coagulase-negative. The isolate was initially identified as Staphylococcus xylosus by Vitek®2 (bioMerieux, Marcy l'Etoile, France). Since this organism is only occasionally isolated from human specimens (3), PCR-based 16S rRNA gene sequencing was undertaken to confirm its identity; the latter test identified the isolate as Staphylococcus cohnii (100% identity, BLAST search). S. cohnii is a novobiocin-resistant, coagulase-negative Staphylococcus that is known to colonize human skin; it has also been frequently identified in the hospital environment (4). The organism is typically methicillin-resistant and frequently harbors plasmids mediating resistance 

